BeOne Medicines AG (BEIGF)
OTCMKTS
· Delayed Price · Currency is USD
24.92
0.00 (0.00%)
At close: Nov 10, 2025
BeOne Medicines AG Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| Revenue | 4,973 | 3,810 | 2,459 | 1,416 | 1,176 | 308.87 | Upgrade
|
| Revenue Growth (YoY) | 50.43% | 54.96% | 73.65% | 20.37% | 280.83% | -27.87% | Upgrade
|
| Cost of Revenue | 686.68 | 594.09 | 379.92 | 286.48 | 164.91 | 1,366 | Upgrade
|
| Gross Profit | 4,286 | 3,216 | 2,079 | 1,129 | 1,011 | -1,057 | Upgrade
|
| Selling, General & Admin | 2,032 | 1,832 | 1,509 | 1,279 | 990.12 | 600.18 | Upgrade
|
| Research & Development | 2,072 | 1,953 | 1,779 | 1,641 | 1,459 | - | Upgrade
|
| Amortization of Goodwill & Intangibles | - | - | - | - | 0.75 | 0.85 | Upgrade
|
| Operating Expenses | 4,104 | 3,785 | 3,287 | 2,919 | 2,450 | 601.02 | Upgrade
|
| Operating Income | 181.87 | -569.01 | -1,209 | -1,790 | -1,439 | -1,658 | Upgrade
|
| Interest Expense | -26.24 | -14.74 | -4.23 | -19.11 | -28.21 | -17.97 | Upgrade
|
| Interest & Investment Income | 46.43 | 62.57 | 78.24 | 71.59 | 12.45 | 19.97 | Upgrade
|
| Earnings From Equity Investments | -18.32 | -10.28 | -7.86 | -3.68 | -1.8 | -0.49 | Upgrade
|
| Other Non Operating Income (Expenses) | 23.92 | 7.35 | -39.49 | -195.13 | 8.31 | 25.5 | Upgrade
|
| EBT Excluding Unusual Items | 207.65 | -524.1 | -1,182 | -1,936 | -1,448 | -1,631 | Upgrade
|
| Gain (Loss) on Sale of Investments | -25.39 | -8.9 | -6.87 | -25.04 | 9.39 | 12.48 | Upgrade
|
| Other Unusual Items | - | - | 362.92 | - | - | - | Upgrade
|
| Pretax Income | 182.26 | -533 | -825.84 | -1,961 | -1,439 | -1,618 | Upgrade
|
| Income Tax Expense | 113.71 | 111.79 | 55.87 | 42.78 | 19.23 | 10.4 | Upgrade
|
| Earnings From Continuing Operations | 68.55 | -644.79 | -881.71 | -2,004 | -1,458 | -1,629 | Upgrade
|
| Minority Interest in Earnings | - | - | - | - | - | 3.62 | Upgrade
|
| Net Income | 68.55 | -644.79 | -881.71 | -2,004 | -1,458 | -1,625 | Upgrade
|
| Net Income to Common | 68.55 | -644.79 | -881.71 | -2,004 | -1,458 | -1,625 | Upgrade
|
| Shares Outstanding (Basic) | 108 | 105 | 104 | 103 | 93 | 83 | Upgrade
|
| Shares Outstanding (Diluted) | 111 | 105 | 104 | 103 | 93 | 83 | Upgrade
|
| Shares Change (YoY) | 6.60% | 0.86% | 1.22% | 11.15% | 11.16% | 38.99% | Upgrade
|
| EPS (Basic) | 0.63 | -6.12 | -8.45 | -19.43 | -15.71 | -19.47 | Upgrade
|
| EPS (Diluted) | 0.58 | -6.12 | -8.45 | -19.43 | -15.71 | -19.47 | Upgrade
|
| Free Cash Flow | 544.6 | -633.29 | -1,719 | -1,822 | -1,562 | -1,401 | Upgrade
|
| Free Cash Flow Per Share | 4.89 | -6.01 | -16.47 | -17.67 | -16.83 | -16.78 | Upgrade
|
| Gross Margin | 86.19% | 84.41% | 84.55% | 79.77% | 85.98% | - | Upgrade
|
| Operating Margin | 3.66% | -14.93% | -49.15% | -126.40% | -122.31% | -536.69% | Upgrade
|
| Profit Margin | 1.38% | -16.92% | -35.86% | -141.52% | -123.93% | -526.10% | Upgrade
|
| Free Cash Flow Margin | 10.95% | -16.62% | -69.93% | -128.68% | -132.76% | -453.57% | Upgrade
|
| EBITDA | 328.17 | -401.98 | -1,125 | -1,727 | -1,393 | -1,626 | Upgrade
|
| EBITDA Margin | 6.60% | -10.55% | -45.74% | -121.94% | -118.44% | - | Upgrade
|
| D&A For EBITDA | 146.31 | 167.03 | 83.94 | 63.05 | 45.49 | 31.79 | Upgrade
|
| EBIT | 181.87 | -569.01 | -1,209 | -1,790 | -1,439 | -1,658 | Upgrade
|
| EBIT Margin | 3.66% | -14.93% | -49.15% | -126.40% | -122.31% | - | Upgrade
|
| Revenue as Reported | 4,973 | 3,810 | 2,459 | 1,416 | 1,176 | 308.87 | Upgrade
|
Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.